Currently, there are 31.23M common shares owned by the public and among those 21.74M shares have been available to trade.
The company’s stock has a 5-day price change of -9.39% and -69.91% over the past three months. ACRV shares are trading -72.76% year to date (YTD), with the 12-month market performance down to -83.30% lower. It has a 12-month low price of $1.30 and touched a high of $10.29 over the same period. ACRV has an average intraday trading volume of 182.06K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.90%, -57.18%, and -74.46% respectively.
Institutional ownership of Acrivon Therapeutics Inc (NASDAQ: ACRV) shares accounts for 66.28% of the company’s 31.23M shares outstanding.
It has a market capitalization of $51.42M and a beta (3y monthly) value of 1.73. The earnings-per-share (ttm) stands at -$2.44. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.67% over the week and 19.38% over the month.
Earnings per share for the fiscal year are expected to decrease by -12.13%, and 5.95% over the next financial year. EPS should grow at an annualized rate of -1.43% over the next five years, compared to -74.96% over the past 5-year period.
Ladenburg Thalmann coverage for the Acrivon Therapeutics Inc (ACRV) stock in a research note released on September 16, 2024 offered a Buy rating with a price target of $16. Ladenburg Thalmann was of a view on April 29, 2024 that the stock is Neutral, while JMP Securities gave the stock Mkt Outperform rating on March 01, 2024, issuing a price target of $14. Jefferies on their part issued Buy rating on December 15, 2023.
